Tengshengbo Pharmaceutical is a biotechnology company dedicated to developing treatments that can solve major public health challenges. Amidst these challenges, large numbers of patients' medical needs are unmet, choices are limited, and social stigma is severe. Since its establishment in 2018, Tengsheng Pharmaceuticals's mission has been to address public health challenges through groundbreaking scientific innovation and insightful patient insight. Tengshengbo Pharmaceutical's mission is very clear: to develop a functional cure for hepatitis B, Tengsheng Pharmaceutical believes this can have a meaningful impact on patients in China and around the world. Tengshengbo Pharmaceutical is cooperating with its partners to promote a strong portfolio of HBV drug candidates, strategically positioning itself as a leading company in the HBV field. The product portfolio includes three differentiated drug candidates: elebsiran (a siRNA under development targeting HBV, previously BRII-835), tobevibart (a broadly neutralizing monoclonal antibody under development, formerly BRII-877), and BRII-179 (a vaccine for HBV treatment based on recombinant proteins). These drug candidates are being tested for various combination treatment options, and each combination treatment may be the best treatment plan aimed at improving the functional cure rate of HBV. Data obtained over the past few years strongly confirm that functional cure for HBV is possible for patients with low HBsAg levels. The combination strategy of Tengshengbo Pharmaceutical combines surface antigen reduction therapy with immunomodulatory therapy to improve the effectiveness of HBV treatment and improve the functional cure rate. Encouraged by the latest data readings and insights, Tengshengbo Pharmaceuticals is advancing all three drug candidates and plans to conduct additional trials by the end of 2024. Based on recognition of the innovation of Tengshengbo Pharmaceutical's HBV product portfolio, all three HBV drug candidates have been certified as breakthrough therapeutic varieties by the Drug Evaluation Center of the China National Drug Administration. These certifications recognize the potential of these candidate drugs to make substantial progress on existing therapies and will accelerate their clinical development and regulatory review. While concentrating resources to maximize the impact of HBV clinical programs, Tengshengbo Pharmaceutical is also actively seeking partners to further develop its non-HBV programs, including HIV, MDR/XDR, and CNS programs.
相关临床试验
11
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2021
进行中（未招募）
2
18.2%
已完成
8
72.7%
招募中
1
9.1%
暂无批准数据
- Brii Bio presented cross-study analysis at APASL 2026 showing that participants achieving HBsAg loss with combination therapies demonstrated favorable off-treatment outcomes with most rebounds below 10 IU/mL. - The analysis of 55 participants from Phase 2 studies revealed that shorter NRTI consolidation periods were not associated with higher rebound rates, suggesting potential for treatment optimization. - Results indicate durable post-treatment immunological control supporting safe discontinuation of NRTIs in pegylated interferon alfa-based combinations with novel therapeutics. - HBV DNA rebound was infrequent with over 90% of participants maintaining viral suppression after NRTI discontinuation without clinically significant liver enzyme elevations.
- Brii Biosciences published Phase 2 ENSURE study results in Nature Medicine showing elebsiran combined with pegylated interferon alfa achieved HBsAg loss rates up to 33.3% compared to 5.6% with interferon monotherapy. - The study demonstrated that patients previously treated with therapeutic vaccine BRII-179 who developed anti-HBs responses had significantly higher HBsAg loss rates of 42.1% versus 8.3% in non-responders. - The combination therapy was generally safe and well-tolerated, with findings suggesting BRII-179 may prime the immune system for improved responsiveness to subsequent curative treatments.
- New data from Brii Bio's Phase 2 ENSURE study reveals that patients who responded to BRII-179 achieved a 55.6% HBsAg seroclearance rate, compared to just 10% in non-responders, supporting a novel patient enrichment strategy. - Combination therapy of elebsiran with PEG-IFNα demonstrated significantly higher HBsAg loss rates (26.3-33.3%) compared to PEG-IFNα alone (5.6%) at 48 weeks in chronic HBV patients. - The findings suggest BRII-179 could serve as a predictive tool to identify patients more likely to respond to curative therapies, potentially improving functional cure rates while reducing unnecessary treatment exposure.
